GLP3, GLP3-R & GLP-3 RT: Research Reference

What do GLP3, GLP3-R and GLP-3 RT mean?

“GLP3” is informal shorthand used online for triple-agonist research. It does not identify a distinct “GLP-3 receptor.” In the retatrutide literature, the three receptor targets are glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Retatrutide is also described by the development identifier LY3437943. Lilly’s retatrutide terminology overview provides manufacturer context.

A similar catalog label does not prove that two suppliers provide identical material. A publication about an investigational compound also does not verify a commercial vial. Keep literature identification and batch identification separate.

The three receptor targets

Retatrutide is studied as an agonist at GIP, GLP-1 and glucagon receptors. “Triple” refers to that receptor profile, not three peptides mixed together or three times the activity of another compound. Receptor activity, experimental conditions and biological endpoints must be interpreted from the methods of the particular study.

For laboratory comparisons, record the compound identifier, model, assay endpoint, controls and analytical documentation. Similar naming or a shared target does not make results interchangeable across cell models, animal studies and clinical trials.

Primary research to start with

• Jastreboff and colleagues, 2023 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity. A randomized phase 2 study published in the New England Journal of Medicine. Use the publication’s methods and limitations when interpreting its findings.
• Rosenstock and colleagues, 2023 — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist. A phase 2 study in type 2 diabetes published in The Lancet; it addresses a different study population and endpoints.
• Sanyal and colleagues, 2024 — Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. A randomized phase 2a report in Nature Medicine examining liver-fat outcomes.
• Bajaj and colleagues, 2026 — TRANSCEND-T2D-1. A phase 3 randomized study in The Lancet. Check the full article for its population, prespecified endpoints and safety reporting.

These references describe research conducted with study materials under their respective protocols. They are not evidence of the identity, purity, safety or performance of a Disguised Alpha batch. This page is a reference list, not an exhaustive review or a clinical recommendation.

How to review a batch certificate

1. Match the identifier. Locate the lot printed on the supplied item and find that same lot in the certificate-of-analysis portal. A report for a different lot should not be treated as verification of the item in hand.
2. Read what was measured. Identify the test method, reported analyte, units, sample description and report date. A chromatographic purity result and a measured quantity are different findings.
3. Check the scope. Do not assume a report covers sterility, endotoxins, residual solvents or other properties unless those tests and results are explicitly included.
4. Keep the original record. Retain the complete report with the lot, supplier record and laboratory receipt date. Resolve a missing or mismatched report before relying on it in an experiment.
5. Document uncertainty. An incomplete report should remain an open question. Contact Disguised Alpha support for the matching record rather than extrapolating from another batch.

GLP-3 RT catalog and related references

For related terminology and original studies, see the GLP2-Tirz / GLP-2 TZ reference and the GLP1-Sema / GLP-1 SM reference.

The GLP-3 RT product page contains the current catalog options. Consult the COA portal for available batch records and quality documentation for the supplier’s stated process. For naming distinctions, read GLP3 vs GLP2: terminology and receptor targets.

Frequently asked questions

Are GLP3-R and GLP3 RT automatically the same material?

No. These are nonstandard catalog and search labels. Compare the stated compound, analytical identity and exact batch records before treating materials as equivalent.

Does “GLP3” mean there is a GLP-3 receptor?

No. In this context, it is informal shorthand around triple-agonist research. The receptor targets discussed here are GIP, GLP-1 and glucagon.

Does a research publication validate a supplier’s product?

No. Literature supports scientific context. Verification of a particular supplied material depends on documentation and testing tied to that material.

Can this guide be used for dosing or treatment?

No. Disguised Alpha products are for laboratory research only and are not for human consumption, veterinary use, diagnosis or treatment. This guide does not provide administration or dosing instructions.

Further research resources

Use PubMed to locate primary publications and the Disguised Alpha Research Hub for related references. Peptide Forum Hub is an external community discussion resource, not a peer-reviewed scientific source. Community posts and directory listings do not establish product quality or safety.

Resource disclosure: the Peptide Forum Hub link is provided in connection with our application to the PeptideSuppliers.org directory. This does not imply directory approval or endorsement.

Editorial standards · Commercial disclosure: this reference is published by Disguised Alpha, which sells laboratory research materials.